Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer

NCT01935921 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01935921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2013
Completion date
July 6, 2018
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii hypopharyngeal squamous cell carcinoma ajcc v7, stage iii laryngeal squamous cell carcinoma ajcc v6 and v7, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iva hypopharyngeal squamous cell carcinoma ajcc v7, stage iva laryngeal squamous cell carcinoma ajcc v7, stage iva oropharyngeal squamous cell carcinoma ajcc v7, stage ivb hypopharyngeal squamous cell carcinoma ajcc v7, stage ivb laryngeal squamous cell carcinoma ajcc v7, stage ivb oropharyngeal squamous cell carcinoma ajcc v7